Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results.
UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in ...
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data The findings, published Tuesday in Nature, are important for another key reason. The team’s work originally ...
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...
Recordamos que fue el pasado mes de diciembre cuando la alcaldesa de Huesca recogía en Madrid el premio GreenWeek, una escultura con forma de baobab rodeado por una escalera infinita, al que ...
Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...
Dinámica Escalera brillante escalera de acceso exterior ... creativo minimalista luz solar Naranja Escalera exterior Casa moderna con estilo arquitectura Contraste de color arquitectura ...
Looking ahead to 2025, Moderna expects revenue of $1.5 to $2.5bn. Credit: Tada Images/Shutterstock. Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024 – a sharp decline from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback